arrow
T

Timothy Ritzmann

University of Nottingham
H指数:12
被引数:737

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Strategic roadmap for delivery of clinical trials in rare childhood central nervous system (CNS) tumours: a multi-stakeholder consensus

罕见儿童中枢神经系统(CNS)肿瘤临床试验交付的战略路线图:一项多利益相关方共识

2026-08-220
OAAI
Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124

更正:Pourroy等人。各年龄段大剂量甲氨蝶呤:安全性、有效性和欧洲HDMTX登记研究的结果。Cancers 2026, 18, 124

Cancers
IF4.4
2026-03-130
OAAI
High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry

全年龄段大剂量甲氨蝶呤:欧洲HDMTX登记研究的安全性、有效性与结局

Cancers
IF4.4
2025-12-310
OAAI
THE MANAGEMENT OF PEDIATRIC AND ADOLESCENT SPINAL EPENDYMOMA; A 20-YEAR NATIONAL EVALUATION INVOLVING UNITED KINGDOM PEDIATRIC ONCOLOGY PRIMARY TREATMENT CENTERS ON BEHALF OF THE UK CHILDREN'S CANCER AND LEUKAEMIA GROUP (CCLG)
2024-06-180
OAAI
OPTIMISING BIOMARKERS FOR ACCURATE EPENDYMOMA DIAGNOSIS, PROGNOSTICATION AND STRATIFICATION WITHIN INTERNATIONAL CLINICAL TRIALS: A BIOMECA STUDY
2023-06-121
OAAI
A MULTICENTER STUDY OF POOR PROGNOSIS CHROMOSOME 1Q GAIN AND/OR 6Q LOSS IN POSTERIOR FOSSA A EPENDYMOMA SHOWS INCREASED PREVALENCE FROM 20% AT DIAGNOSIS TO 60% AT FIRST RECURRENCE
2023-06-120
OAAI
Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study

后颅窝A组室管膜瘤复发时高危染色体1q增加和6q丢失显著增加: 一项多中心研究

2023-05-295
OA
Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study
2023-03-142
OAAI
Spatial transcriptomic analysis delineates epithelial and mesenchymal subpopulations and transition stages in childhood ependymoma

空间转录组学分析描绘了儿童室管膜瘤的上皮和间充质亚群以及过渡阶段

2022-10-1010
OA
Recurrent ACVR1 mutations in posterior fossa ependymoma

后颅窝室管膜瘤的复发性ACVR1突变

2022-05-198
OA
SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort-A BIOMECA Consortium Study

SIOP室管膜瘤I: 试验队列的最终结果,长期随访和分子分析-BIOMECA联盟研究

2022-01-0918
OAAI